Exscientia Plc (EXAI) has released an update.
Exscientia Plc reports positive early Phase 1 results for its PKC-theta inhibitor program and anticipates further clinical advancements in its oncology-focused pipeline, including a CDK7 inhibitor and two other programs expected to enter clinical trials by early 2025. The integration of AI and full experiment automation is enhancing drug design capabilities, while cost-saving measures are projected to save the company $40 million annually. The company’s strategic collaborations continue to progress, with Exscientia receiving a $4 million payment from Sanofi and expecting extended financial runway into 2027.
For further insights into EXAI stock, check out TipRanks’ Stock Analysis page.
